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We attempted to determine whether b1,3-galactosyl-
transferase b3Gal-T5 is involved in the biosynthesis of a
specific subset of type 1 chain carbohydrates and ex-
pressed in a cancer-associated manner. We transfected
Chinese hamster ovary (CHO) cells expressing Fuc-TIII
with b3Gal-T cDNAs and studied the relevant glycocon-
jugates formed. b3Gal-T5 directs synthesis of Lewis type
1 antigens in CHO cells more efficiently than b3Gal-T1,
whereas b3Gal-T2, -T3, and -T4 are almost unable to
direct synthesis. In the clone expressing Fuc-TIII and
b3Gal-T5 (CHO-FT-T5), sialyl-Lewis a synthesis is
strongly inhibited by swainsonine but not by benzyl-
a-GalNAc, and sialyl-Lewis x is absent, although it
is detected in the clones expressing Fuc-TIII
and b3Gal-T1 (CHO-FT-T1) or Fuc-TIII and b3Gal-T2
(CHO-FT-T2). Endo-b-galactosidase treatment of N-
glycans prepared from clone CHO-FT-T5 releases
(6NeuAca233)Galb133[Fuca134]GlcNAcb133Gal but
not GlcNAcb133Gal or type 2 chain oligosaccharides,
which are found in CHO-FT-T1 cells. This result indi-
cates that b3Gal-T5 expression prevents poly-N-
acetyllactosamine and sialyl-Lewis x synthesis on N-
glycans. Kinetic studies confirm that b3Gal-T5 prefers
acceptors having the GlcNAcb133Gal end, including
lactotriosylceramide. Competitive reverse transcriptase
mediated-polymerase chain reaction shows that the
b3Gal-T5 transcript is expressed in normal colon mu-
cosa but not or poorly in adenocarcinomas. Moreover,
recombinant carcinoembryonic antigen purified from a
CHO clone expressing Fuc-TIII and b3Gal-T5 reacts with
anti-sialyl-Lewis a and carries type 1 chains on oligosac-
charides released by endo-b-galactosidase. We conclude
that b3Gal-T5 down-regulation plays a relevant role in
determining the cancer-associated glycosylation pat-
tern of N-glycans.
Type 1 chain oligosaccharides found in N- and O-glycans, as
well as in glycolipids, contain the distinctive Galb133GlcNAc
disaccharide as their core structure. It is synthesized by b1,3-
galactosyltransferases (b1,3Gal-Ts),1 a family of enzymes
whose genes have been cloned very recently (1). The functional
role of type 1 chains is not known, but several studies have
indicated that some of them are differentially expressed in
cancer. In particular, CEA expressed in colon cancer is charac-
terized by the absence of such chains (2), which are abundantly
present on the N-glycans of its normal counterparts synthe-
sized by healthy colon mucosa, also referred to as the non-
specific cross-reacting antigen-2 (3) and the normal fecal anti-
gen-2 (4). At this regard, a b1,3Gal-T activity measured using
GlcNAcb133Galb134Glc as acceptor was found lower in ad-
enocarcinomas than in normal mucosa (5). However, type 1
chain Lewis antigens sialyl-Lewis a (sLea) and Leb are consid-
ered tumor markers (6), and serum levels of sLea (CA19-9
antigen) are used for clinical diagnosis and follow-up of epithe-
lial cancers of the gastrointestinal tract (7). sLea from cancer
patient serum was found on mucins (8), and it is reported on
both mucins (9) and glycolipids (10) in adenocarcinoma cell
lines. Five b3Gal-T cDNAs are presently available. b3Gal-T1,
cloned first from melanoma cells (11) and then from colon
carcinoma cells (12), as well as b3Gal-T2 (13), were found to
synthesize sLea in CHO cells but to be very poorly expressed in
cancer cell lines expressing sLea. b3Gal-T3 and -T4 (14) were
found expressed in various tissues, including colon and pan-
creas and in some cancer cell lines, but the expression levels do
not correlate with those of type 1 chain Lewis antigens. More-
over, there is no evidence yet for their ability to synthesize the
type 1 chain. In particular, b3Gal-T3 was very recently re-
ported as a GalNAc transferase involved in globoside biosyn-
thesis and renamed b3GalNAc-T1 (15). b3Gal-T5, cloned from
colon carcinoma cells, was found to direct synthesis of sLea in
different cell lines, and its expression levels correlate with
those of Lewis type 1 antigens in cancer cell lines from colon
and pancreas (16). This enzyme was suggested to be the one
previously characterized as the b1,3Gal-T active on glycolipids
(17) and GlcNAc (18, 19), and involved in the synthesis of core
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3 O-glycans (20). The above data led to the working hypothesis
that the biosynthesis of different type 1 chain oligosaccharides
may depend on the expression of different and differentially
regulated b3Gal-Ts. In particular, an enzyme able to act on
N-glycans would be expected to be less active in cancer than in
normal mucosa, whereas another active on O-glycans should be
more expressed in cancer.
To evaluate whether b3Gal-T5 is actually involved in the
biosynthesis of a specific subset of type 1 chain oligosaccharides
and expressed in a cancer-associated manner, we have
transiently transfected CHO cells expressing Fuc-TIII with
b3Gal-T cDNAs and compared the relative ability of enzymes
to direct synthesis of Lewis type 1 antigens. We then con-
structed CHO clones permanently expressing Fuc-TIII and
b3Gal-T5, Fuc-TIII and b3Gal-T2, or Fuc-TIII and b3Gal-T1,
determined the effect of drugs affecting glycosylation on anti-
gen expression, and characterized the oligosaccharides that
became radioactive in some clones upon metabolic labeling
with tritiated Gal. Moreover, we studied the substrate speci-
ficity of b3Gal-T5 by calculating the kinetic constants toward
different acceptors, and measured the expression levels of the
transcript in colon adenocarcinomas and surrounding normal
mucosa by competitive RT-PCR. We further modified the CHO
clone expressing b3Gal-T5 to make it able to stably express
human CEA and investigated the presence of type 1 chains in
CEA purified from such clone.
EXPERIMENTAL PROCEDURES
Materials—GlcNAcb133Galb134Glc was prepared by digesting
lacto-N-tetraose (IsoSep, Lund, Sweden), 5 mg/ml, in 0.1 M citrate
phosphate buffer, pH 4.5, with 40 milliunits/ml bovine testis b-galacto-
sidase (Sigma), for 20 h at 37 °C. The obtained trisaccharide was puri-
fied from Gal and unreacted lacto-N-tetraose by repeated Bio-Gel P-2
columns monitored by HPTLC, as reported (21). Lactotriosylceramide
was prepared by digesting lacto-N-neotetraosylceramide, 4 mg/ml, in 50
mM cacodylate/HCl buffer, pH 6.5, with Diplococcus pneumoniae b-ga-
lactosidase (Sigma), 0.2 units/ml for 20 h at 37 °C. The obtained com-
pound was purified by a Silica-Gel column (0.7 3 50 cm) using chloro-
form/methanol/water, 55:20:3 (v/v), as the eluting solvent system.
Lacto-N-neotetraosylceramide was prepared by digesting sialyl-lacto-
N-neotetraosylceramide, 5 mg/ml, in 0.1 M sodium cacodylate buffer, pH
6.0, with Clostridium perfringens sialidase, 1 unit/ml, for 20 h at 37 °C.
Ganglioside sialyl-lacto-N-neotetraosylceramide was purified from bo-
vine erythrocytes using the procedure reported by Chien et al. (22).
GlcNAcb132Man was from Dextra Laboratories (Reading, UK),
GlcNAcb133Galb13O-methyl and GlcNAcb136Mana3O-methyl
were from Sigma. Anti-sLex monoclonal antibody was precipitated from
the culture media of hybridoma CSLEX1 (ATCC HB-8580) by ammo-
nium sulfate, resuspended, dialyzed, and kept at a concentration of 2
mg/ml. Anti-Lea and anti-sLea monoclonal antibodies were as reported
(12, 19). Mouse monoclonal anti-CEA (clone COL-1) was from NeoMar-
kers (Lab Vision, Italy).
Cell Cultures, Transfections, and Treatments—CHO cells expressing
Polyoma virus T antigen and Fuc-TIII (CHO-T-FT), COLO-205, and
WM266-4 cells were cultured as described previously (12, 19). Human
gastric adenocarcinoma MKN-45 cells (a gift of C. Ponzetto, University
of Turin), were cultured in RPMI 1640 medium containing 10% fetal
bovine serum, 100 units/ml penicillin, 1.0 mg/ml streptomycin, and 2
mM L-Glu. For transient transfection, 2.0 3 105 CHO-T-FT cells were
plated in 12-well plates 20 h before transfection, washed with serum
free a-minimal essential medium, and incubated with 0.5 ml of trans-
fection solution for 3 h under usual growing conditions. Transfection
solutions, containing 1 mg/ml b3Gal-T cDNA in pcDNAI or pCDM8
vectors plus 0.065 mg/ml pcDNAI-Luc and 18 ml/ml DOTAP (Roche
Molecular Biochemicals) were prepared and used as reported previ-
ously (12). Seventy-two hours after transfection, cells were harvested,
washed, and resuspended with PBS. One-tenth of resuspended cells
was processed for luciferase activity determination, using a commercial
kit (Luciferase assay system, Promega) according to the manufacturer’s
recommendations. The remaining material was stained and analyzed
by flow cytometry as previously reported (12, 19). For treating cell lines
and clones with drugs affecting glycosylation, 1 3 105 cells were plated
in 12-well plates and incubated overnight, and the medium was re-
placed with medium containing 0.1 mg/ml swainsonine (Sigma), 2 mM
benzyl-a-GalNAc (Sigma), or 2 mM sodium butyrate. After 48 h, me-
dium was replaced with fresh medium containing drugs. After addi-
tional 48 h, cells were collected, stained, and analyzed by flow
cytometry (19).
Construction of CHO Clones—CHO clones expressing either Fuc-TIII
and b3Gal-T5 (CHO-FT-T5), Fuc-TIII and b3Gal-T2 (CHO-FT-T2), or
Fuc-TIII and b3Gal-T1 (CHO-FT-T1) were obtained by the calcium
phosphate transfection method (23), using a modification of the proce-
dure reported (24). Briefly, the DNA mixture (20 mg) contained 1 mg of
EcoRI-linearized pSV2Neo, 10 mg of ScaI-linearized pcDNAI/
Fuc-TIII, and 10 mg of ScaI-linearized pCDM8/b3Gal-T5, or 10 mg of
KpnI-linearized pCDM8/b3Gal-T2, or 10 mg of ScaI-linearized
pcDNAI/b3Gal-T1, respectively. Upon selection with 0.4 mg/ml active
G418, 30 (CHO-FT-T5 and CHO-FT-T1) or 60 colonies (CHO-FT-T2)
were collected using cloning cylinders, grown in tissue culture slides,
stained with anti-sLea or anti-Lea antibody followed by secondary
FITC-conjugated anti-mouse IgG, and analyzed by fluorescence micros-
copy. Two or three positive colonies were subcloned by limiting dilution
in 96-well plates, and several subclones were analyzed as above. sLea
and Lea expression on positive colonies was quantitated by flow cytom-
etry. Single colonies expressing a constant level of sLea and Lea, named
CHO-FT-T5, CHO-FT-T2, and CHO-FT-T1, respectively, were selected
and used for further characterization and experiments. CHO cells ex-
pressing CEA (CHO-FT-T5-CEA) were obtained from clone CHO-FT-T5
by the transfection procedure described above but using 20 mg of KpnI-
linearized pCDM8-CEA and 1 mg of pHA58 plasmid in the DNA mix-
ture, and 0.5 mg/ml hygromycin B (Roche Molecular Biochemicals) for
selection. pHA58 plasmid, a generous gift of P. Morandini (University of
Milan), was derived from pSV72 vector and had the hygromycin B gene
under the control of mouse phosphoglycerate kinase-1 promoter. Mono-
clonal anti-CEA antibody was used, at 1:100 dilution, for cell staining.
DNA Preparation—b3Gal-T1 cloning in pcDNAI vector has been
previously reported (12). For b3Gal-T2, -T3, -T4, -T5, and CEA cloning,
the corresponding coding sequences were amplified using single-
stranded cDNA as template, obtained by reverse transcription of total
RNA extracted (12) from WM266-4 (b3Gal-T2), MKN-45 (b3Gal-T3 and
CEA), or COLO-205 cells (b3Gal-T4 and -T5), in a reaction mixture
containing, in 40-ml volume, 50 mM Tris-HCl, pH 8.3, 50 mM KCl, 5 mM
MgCl2, 1000 units/ml human placental ribonuclease inhibitor, 1 mM of
each deoxynucleotide triphosphate, 0.4 mM oligo(dT)16 primer, 1000
TABLE I
Oligonucleotide primers used for competitive RT-PCR analysis
Target gene Primer pairsa
PCR products Restriction sites
for competitorTarget Competitor
bp
b3Gal-T2 F: 59-GCCAAAAGGTCTCTGTTCCGCACTC-39 817 556 NdeI/PstI
R: 59-GATTGGGTGCATATCCTCGCATTAGG-39
b3Gal-T3 F: 59-CTGGTGACCTCCCACCCTTCAGATG-39 740 632 XmnI/PstI
R: 59-GCATGTGGTGTTCCTTAGCATGACCTGC-39
b3Gal-T4 F: 59-CCAGAGAAACGCCATTCGGGCTTCGTG-39 526 416 SmaI/EcoRV
R: 59-AGGGTGGAAAGGGGCCCCAGGTG-39
b3Gal-T5 F: 59-CAGATACAGACTGCAGGCAGACACCTCC-39 709 480 XmnI
R: 59-GCAGGCCACGATCCTCCTGAAGAGGC-39
Mouse b-actin F: 59-GCACCCTGTGCTGCTCACCGAGGC-39 813 534 RcaI
R: 59-GTGCACGATGGAGGGGCCGGACTC-39
a F, forward primer; R, reverse primer.
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units/ml avian myeloblastosis virus reverse transcriptase (Amersham
Pharmacia Biotech), and freshly denatured total RNA (250 mg/ml) as
template. Reactions were kept for 90 min at 42 °C. Amplifications were
performed in the presence of a commercially available “high fidelity”
Taq polymerase (LA Taq, Takara), according to the manufacturer’s
protocol, using 2.5 mg/ml of each oligonucleotide primer, deduced from
published sequences, and 4 ml of reverse transcription reaction for each
100 ml of amplification mixture. PCR reactions were incubated as fol-
lows: a single treatment at 94 °C for 3.5 min followed by a cycle con-
sisting of 1.5 min at 94 °C (melting), 2.0 min at 62 °C (annealing), and
2.5 min at 72 °C (extension), repeated 30 (b3Gal-Ts) or 15 times (CEA);
a final extension step was performed at 72 °C for 8 min. The amplified
DNA was digested with HindIII and XbaI (b3Gal-T3) or ligated to BstXI
adaptors (all others), and cloned in pcDNAI (b3Gal-T3) or pCDM8
vectors (all others) using a procedure reported previously (12). Direct
DNA sequencing of the obtained constructs, performed by the
dideoxynucleotide chain-termination method using an automated pro-
cedure, indicated that the coding sequences are identical to those pub-
lished. pcDNAI-Luc, expressing the luciferase gene, was constructed by
removing the luciferase coding sequence from plasmid pGL3 (Promega)
using HindIII and XbaI, and subcloning into the corresponding sites of
pcDNAI vector.
Enzyme Assays and Reaction Product Characterization—b3Gal-T5
and Fuc-TIII were assayed in cell clones as previously reported (19). For
kinetic analysis, b3Gal-T5 was assayed upon transfection of pCDM8-
b3Gal-T5 in COS-7 cells. Cells were transfected, harvested, washed,
resuspended, and used as the enzyme source, as described previously
(21). Enzyme activity was determined in a reaction mixture containing,
in a final volume of 10 ml, 0.1 M Tris/HCl buffer, pH 7.0, 10 mM MnCl2,
0.5 mg/ml Triton X-100, 1 mg/ml a-lactalbumin, 5 mM CDP-choline, 0.8
mM donor UDP-[3H]Gal, specific radioactivity (10 mCi/mmol), and 0.2–
1.0 mg/ml cell protein, in the presence of different acceptors at various
concentrations. In the case of glycolipid acceptor, it was dissolved in
chloroform/methanol, 4:1 (v/v), mixed in the reaction tube with 15 mg of
Triton CF-54 dissolved in the same solvent, and dried before adding the
reaction mixture. Incubations were done at 37 °C for 60 min. At the end
of incubation, reaction products were assayed by Dowex chromatogra-
phy (oligosaccharide acceptors) or descending paper chromatography
(glycolipid acceptor) according to previously reported protocols (19, 25).
The oligosaccharide reaction products were identified by pooling several
Dowex eluates, which were lyophilized and purified by Bio-Gel P-2
chromatography (21). The obtained saccharides were treated with D.
pneumoniae or Xanthomonas manihotis b-galactosidases, specific for
b1,4- and b1,3-linkages, respectively, and analyzed using a Bio-Gel P-2
column (19). Reaction product with glycolipid acceptor, pooled from
several reactions, was purified by Sep-Pack C-18 cartridge, desalted by
partitioning in chloroform/methanol/water, 2:1:1 (v/v), and analyzed by
HPTLC, using chloroform/methanol/water, 60:35:8 (v/v), as eluting sol-
vent system, and visualized by fluorography (25).
Metabolic Labeling and Carbohydrate Analysis—CHO clones (2.0 3
106 cells) were plated in 60-mm dishes containing 0.1 mCi of [3H]Gal
(Amersham Pharmacia Biotech) in 2.5 ml of culture medium and incu-
bated 40 h under regular conditions. Labeled cells were harvested as for
immunostaining, resuspended in PBS at a density of 4 3 106 cells/0.1
ml, and kept frozen until used. N-Glycans were released from cell
suspension by N-glycanase (Glyko) digestion of the material denatured
by heating in the presence of SDS, under the conditions recommended
by the manufacturer. Released N-glycans were isolated by a Sep-Pak
C-18 cartridge and further purified by Sephadex G-50 chromatography,
as reported (24). Oligosaccharides released by endo-b-galactosidase
were characterized following the procedure reported by Seuyoshi et al.
(26) with some modifications. Purified N-glycans were passed through a
Bio-Gel P-4 column (0.7 3 50 cm), and only the radioactivity eluted with
water as a peak close to the exclusion volume was collected, lyophilized,
and used for characterization. Endo-b-galactosidase digestion was per-
formed on radioactive N-glycans, 10,000–20,000 cpm/ml, using the en-
zyme from Bacteriodes fragilis (Glyko), 0.5 milliunit/ml, in the buffer
supplied by the manufacturer, for 20 h at 37 °C. The reaction mixture
was then applied to the same Bio-Gel P-4 column as above, and the
radioactivity was eluted with the exclusion volume collected and re-
ferred to as the endo-b-galactosidase resistant N-glycans, whereas the
radioactivity eluted as oligosaccharides was applied to a QAE-Sephadex
column to separate neutral and charged sugars, according to a previous
procedure (26). Material collected in the flow-through was referred to as
the neutral oligosaccharides, whereas that eluted with NaCl was col-
lected, desalted on a Bio-Gel P-2 column, and treated with Newcastle
disease virus sialidase. Neutral and de-sialylated oligosaccharides were
analyzed by a Bio-Gel P-4 column (0.7 3 100 cm), eluted with water at
a flow rate of 0.1 ml/min, 4.5 min/fraction. The obtained peaks were
collected, lyophilized, and treated with glycohydrolases for character-
ization. X. manihotis b-galactosidase (Glyko), almond meal a-fucosidase
(Oxford Glycosystem), D. pneumoniae b-N-acetylglucosaminidase
(Glyko), D. pneumoniae b-galactosidase (Sigma), and Newcastle disease
virus sialidase (Glyko) digestions were performed on radioactive oligo-
saccharides, 1000–2000 cpm/ml, according to the procedures reported
(19, 26). The amount of Gal released by glycohydrolase treatment of
endo-b-galactosidase-resistant N-glycans was determined as reported
(19). Glycohydrolase digestions of the tetrasaccharide obtained from
clone CHO-FT-T5 were analyzed using a Bio-Gel P-2 column (0.7 3 100
cm) eluted with water at a flow rate of 0.1 ml/min, 4.5 min/fraction,
whereas those of the peaks were collected from CHO-FT-T1 using a
Bio-Gel P-4 column (0.7 3 100 cm) under the same conditions.
CEA Purification and Characterization—CEA was extracted and
purified following a published procedure (27). Briefly, about 2.5 3 107
metabolically labeled cells, prepared as above described, were diluted to
1.5 3 107 cells/ml in PBS, homogenized by vortexing 1 min, and treated
with 0.1 unit/ml phosphatidylinositol phospholipase C (Glyko) at 37 °C
for 2 h. Total reaction was spun at 14,000 rpm for 10 min, and the
supernatant was collected, made 0.6 M with perchloric acid, and centri-
fuged as above. The clear supernatant was neutralized with NaOH,
freeze-dried, resuspended, and loaded onto a Sepharose CL6B column
equilibrated and eluted with 50 mM PBS, pH 5.2. Elution was moni-
tored by liquid scintillation counting, and relevant fractions were ana-
lyzed by SDS-PAGE and visualized by fluorography. Western blotting
FIG. 1. Flow cytometry analysis of CHO-T-FT cells transiently
cotransfected with different b3Gal-T and luciferase cDNAs.
CHO-T-FT cells, expressing Polyoma virus T antigen and human Fuc-
TIII, were transfected using liposomes containing a 15:1 mixture of
individual b3Gal-T and luciferase cDNAs, each cloned in pCDM8 or
pcDNAI expression vectors. Seventy-two hours later, cells were har-
vested and stained with anti-sLea (solid line) or anti-Lea (stippled line)
monoclonal antibodies followed by FITC-conjugate anti-mouse IgG sec-
ondary antibody, or with secondary antibody alone (dotted line), and
analyzed by flow cytometry. An aliquot of the same cells was homoge-
nized and used for luciferase activity assay.
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was performed as previously reported (24) using monoclonal anti-CEA
(1:200), anti-sLea (1:500), and anti-sLex (1:100) antibodies, followed by
peroxidase-conjugated goat anti-mouse immunoglobulin (Amersham
Pharmacia Biotech) (1:2000). ECL was developed with Renaissance
chemiluminescence reagent (PerkinElmer Life Sciences). Homogeneous
fractions were collected, lyophilized, and desalted on a Bio-Gel P-2
column. Purified [3H]CEA was treated with C. perfringens sialidase and
almond meal a-fucosidase, and then with endo-b-galactosidase, under
the conditions reported for N-glycan digestion. The reaction mixture
was then applied to a Bio-Gel P-2 column (0.7 3 50 cm), eluted with
water at a flow rate of 0.13 ml/min, 2.5 min/fraction. The obtained
peaks, as well as the total purified CEA, were treated with b-galacto-
sidases and analyzed by Bio-Gel P-2 chromatography as above
described.
Competitive RT-PCR Analysis—For the analysis of human samples,
bioptic specimens were collected at surgery, immediately frozen in dry
ice, and placed in liquid nitrogen until used. For RNA extraction, 1–2
mm3 of material was homogenized with a rotary homogenizer in 0.5 ml
of the lysis buffer from a Qiagen RNeasy minikit and processed in the
presence of DNase according to the manufacturer’s recommendations.
First strand cDNA was synthesized by Moloney murine leukemia virus
reverse transcriptase (Amersham Pharmacia Biotech) as previously
reported (12). Control reactions were prepared by omitting the reverse
transcriptase in the mixture. First strand cDNA was amplified in a
50-ml reaction and in the presence of 20 fg of competitor for 35 cycles
(glycosyltransferases) or 5 pg of competitor for 25 cycles (b-actin), under
the conditions reported (12). No amplification was detected when the
control reactions were used as template. Human b-actin, Fuc-TIII,
FUT2, and b3Gal-T1 competitors and oligonucleotide primers used
were the same as those described in a previous study (12). b3Gal-T2,
-T3, -T4, -T5, and mouse b-actin oligonucleotide primers, as well as the
restriction enzymes used for competitor preparation, are listed in Table
I. Quantification of human b3Gal-T5, b3Gal-T2, b3Gal-T1, and Fuc-
TIII transcripts in CHO clones was performed by the same procedure
but using 60 fg of each glycosyltransferase competitor, or 20 pg of mouse
b-actin competitor, in 50-ml reactions that were amplified for 30 (gly-
cosyltransferases) or 25 cycles (b-actin).
RESULTS
Biosynthesis of sLea and Lea in CHO Cells Transiently Trans-
fected with b3Gal-T cDNAs—The ability of different cloned
b3Gal-Ts to synthesize the type 1 chain was assessed to deter-
mine the amount of sLea and Lea antigens expressed upon
cDNA transfection on the surface of CHO-T-FT cells, a clone
permanently expressing Fuc-TIII and Polyoma virus T antigen.
For this purpose, cells were transiently cotransfected with
b3Gal-T and reporter luciferase cDNAs both placed in expres-
sion vectors having the Polyoma virus origin of replication.
Luciferase activity from different transfections ranged between
0.6 and 1.4 units. Despite such differences in transfection effi-
ciency, both sLea and Lea antigens were easily detected in cells
transfected with b3Gal-T5 (very bright) and b3Gal-T1, poorly
detected with b3Gal-T2, and not at all detected with b3Gal-T3
and b3Gal-T4. In a typical experiment (Fig. 1), a peak repre-
senting up to 35% of cells transfected with b3Gal-T5 appears
intensely bright mostly after anti-sLea antibody staining. Flu-
orescence intensity on positive cells was much lower upon
b3Gal-T1 transfection, and faintly or not detectable in the
other cases, although transfection efficiency was similar or
sometimes higher, as assessed by luciferase activity assay.
These results suggest that different substrate specificity exists
among the different b3Gal-Ts, and only b3Gal-T5 finds large
amount of suitable acceptors in CHO cells.
Construction and Characterization of CHO Clones Express-
ing b3Gal-T5 and Fuc-TIII, b3Gal-T2 and Fuc-TIII, or b3Gal-
T1 and Fuc-TIII—To evaluate the hypothesis that the amount
of sLea and Lea antigens expressed in CHO cells transfected
with b3Gal-Ts reflects the availability of the proper precursors,
we constructed three CHO clones permanently expressing the
antigens upon stable transfection with either b3Gal-T5 and
Fuc-TIII, b3Gal-T2 and Fuc-TIII, or b3Gal-T1 and Fuc-TIII. All
clones, named CHO-FT-T5, CHO-FT-T2, and CHO-FT-T1, re-
spectively, express human Fuc-TIII transcript in a similar
amount, as determined by competitive RT-PCR, whereas each
clone expresses only its corresponding human b3Gal-T tran-
script (Fig. 2A). Flow cytometry analysis (Fig. 2B) of the ob-
tained clones shows intense and homogeneous staining with
anti-sLea and anti-Lea antibodies in CHO-FT-T5 cells, weak
and heterogeneous staining in CHO-FT-T1, and very faint
staining in CHO-FT-T2 despite the high expression level of the
transcript, thus providing fluorescence patterns very similar to
FIG. 2. Characterization of CHO-FT-T5, CHO-FT-T2, and CHO-
FT-T1 clones. CHO clones permanently expressing human Fuc-TIII
and b3Gal-T5 (CHO-FT-T5), Fuc-TIII and b3Gal-T2 (CHO-FT-T2), or
Fuc-TIII and b3Gal-T1 (CHO-FT-T1) were constructed as described
under “Experimental Procedures.” A, total RNA was extracted from the
clones and reverse-transcribed, and the obtained first strand cDNA was
amplified by PCR using primers specific for human glycosyltrans-
ferases or mouse b-actin, in the presence of the proper competitor DNA.
One-fifth aliquot of each PCR reaction was analyzed by 1% agarose gel
electrophoresis, visualized by staining with ethidium bromide, and
photographed, and the spots were quantitated by densitometric scan-
ning of the negative film. The amounts of amplified target cDNAs were
calculated from their respective standard curves and normalized by
those for b-actin. B, cell clones were stained with monoclonal anti-sLea
(solid line), anti-Lea (dotted line) (both IgG), or anti-sLex (stippled line)
(IgM) monoclonal antibody, followed by FITC-conjugate anti-mouse IgG
or IgM, respectively, and analyzed by flow cytometry. Negative controls
(shaded areas) represent the cell clones stained with FITC-conjugate
anti-mouse IgG alone.
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those obtained by the transient transfection experiments (Fig.
1). Moreover, CHO-FT-T2 and CHO-FT-T1 cells are homoge-
neously bright with anti-sLex staining, as expected in CHO
cells expressing Fuc-TIII, whereas CHO-FT-T5 cells are totally
negative (Fig. 2B). This last result is surprising and suggests a
competition between Gal-Ts in the synthesis of type 1 versus
type 2 chain Lewis antigens.
Effect of Drugs Affecting Glycosylation on the Expression of
sLea and sLea in CHO Clones—CHO cells are known to express
mostly complex type N-glycans and simple core 1 type O-gly-
cans (28). Because the latter are not precursors of type 1
chains, our findings suggest that b3Gal-T5 has a distinctive
ability to act on complex type N-glycans. To address this issue
and to study the contribute of N- and O-linked glycosylation on
the expression of sLea and sLex, cells were treated with swain-
sonine and benzyl-a-GalNAc, selectively affecting complex type
N-glycan and O-glycan biosynthesis, respectively, before stain-
ing with anti-sLea or anti-sLex antibodies. sLea staining is 80%
inhibited by swainsonine treatment in CHO-FT-T5, whereas
benzyl-a-GalNAc treatment is ineffective and sLex staining is
absent (Fig. 3). Conversely, in clone CHO-FT-T2 sLea staining
is almost absent, whereas sLex staining is reduced by swain-
sonine treatment (about 65%) and slightly stimulated by so-
dium butyrate. In clone CHO-FT-T1 sLea staining is almost
70% inhibited by benzyl-a-GalNAc, whereas swainsonine treat-
ment is ineffective; moreover, sodium butyrate treatment stim-
ulates sLea synthesis 5-fold. sLex staining in this clone is re-
duced by swainsonine treatment and slightly stimulated by
sodium butyrate, as in CHO-FT-T2. In control COLO-205 cells,
sLea and sLex reactivity is totally abolished by benzyl-a-Gal-
NAc, and only about 30% inhibited by swainsonine treatment
(Fig. 3). These results indicate that sLea expressed in CHO-
FT-T5 cells is carried by complex type N-glycans, presumably
TABLE II
Radioactivity distribution in CHO clones metabolically
radiolabeled with [3H]Gal







Total cell incorporation 6.2 (100) 8.4 (100) 7.9 (100)
N-Glycans 5.2 (83.8) 6.4 (76.2) 6.2 (78.4)
Oligosaccharides
Endo-b-galactosidase-sensitive 1.2 (19.3) 1.6 (19.0) 1.5 (18.9)
Neutrala 0.84 (13.5) 1.0 (11.9) 0.92 (11.6)
Chargedb 0.39 (6.3) 0.52 (6.2) 0.55 (6.9)
a Unbound to QAE-Sephadex.
b Bound to QAE-Sephadex.
FIG. 3. Effect of drugs affecting glycosylation on the expres-
sion of sLea and sLex antigens in different cells. Cells were grown
under regular conditions (controls), in the presence of 0.1 mg/ml swain-
sonine, 2 mM benzyl-a-GalNAc, or 2 mM sodium butyrate. At the end of
incubation, cells were harvested, stained, and analyzed by flow cytom-
etry as in Fig. 2.
FIG. 4. Characterization of radioactive oligosaccharides re-
leased by endo-b-galactosidase. Upper panel, the neutral radioac-
tive oligosaccharides released by endo-b-galactosidase from the N-gly-
cans isolated from CHO-FT-T5 (empty circles) or CHO-FT-T1 (solid
circles), were submitted to Bio-Gel P-4 filtration. Lower panel, the peak
from CHO-FT-T5 cells eluted at the tetrasaccharide size (fractions
55–59 in upper panel) was submitted to Bio-Gel P-2 chromatography
upon no treatment (empty circles), almond meal a-fucosidase digestion
(full circles), almond meal a-fucosidase plus X. manihotis b-galactosid-
ase digestion (empty squares), or to almond meal a-fucosidase plus X.
manihotis b-galactosidase and D. pneumoniae b-N-acetylglucosamini-
dase digestion (full squares). Calibration of each column is indicated at
the top of each panel. Tetrasaccharide, Galb134GlcNAcb133
Galb134Glc; trisaccharide, Fuca132Galb133GlcNAc; disaccharide,
Galb133GlcNAc; monosaccharide, Gal.
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the same carrying the sLex epitope in CHO-FT-T1 and CHO-
FT-T2 cells.
Characterization of Complex N-Glycans Formed in Clone
CHO-FT-T5—To investigate the actual nature of the saccha-
rides used as substrates by b3Gal-T5 in CHO cells, we studied
the radioactive structures formed upon metabolic labeling with
[3H]Gal in CHO-FT-T5 as well as in CHO-FT-T1 and CHO-
T-FT cells, a clone not expressing b1,3Gal-T but Fuc-TIII only.
The N-glycans were prepared from the total incorporated ra-
dioactivity and treated with endo-b-galactosidase, and the re-
leased oligosaccharides were separated in the neutral and
charged fractions. As shown in Table II, the radioactivity re-
covered after each step is rather similar in the three clones. On
the other hand, the composition of the neutral saccharides
released by endo-b-galactosidase treatment of CHO-FT-T5
N-glycans is dramatically different from that of CHO-FT-T1
N-glycans. In fact, almost all radioactivity derived from clone
CHO-FT-T5 is eluted as a single peak in the area of tetrasac-
charides by Bio-Gel P-4 fractionation, whereas that from clone
CHO-FT-T1 is distributed in several peaks, including some of
higher molecular weight as well as one in the disaccharide area
(Fig. 4, upper panel). The radioactive peak obtained from CHO-
FT-T5 N-glycans is converted to a trisaccharide by almond
meal a-fucosidase, to an equal mixture of disaccharide and
monosaccharide by the action of both almond meal a-fucosidase
and X. manihotis b-galactosidase, and to a monosaccharide by
the combination of the above enzymes and D. pneumoniae
b-N-acetylglucosaminidase (Fig. 4, lower panel). Digestion of
the tetrasaccharide peak with almond meal a-fucosidase and
D. pneumoniae b-galactosidase determines the formation of a
single peak in the area of trisaccharides but not detectable
monosaccharides (not shown). The elution profile obtained af-
ter de-sialylation of the charged oligosaccharides is identical,
indicating that Galb133[Fuca134]GlcNAcb133Gal and
NeuAca233Galb133[Fuca134]GlcNAcb133Gal account for
the vast majority of oligosaccharides released by endo-b-galac-
tosidase digestion of the N-glycans formed in clone CHO-FT-
T5. However, the elution profile of the oligosaccharides re-
leased by endo-b-galactosidase treatment of CHO-FT-T1 and
CHO-T-FT cells are very similar. Among such peaks, the one
eluted as a disaccharide was identified as GlcNAcb133Gal,
because it is converted to a monosaccharide by D. pneumoniae
b-N-acetylglucosaminidase. Such a disaccharide is formed by
the action of endo-b-galactosidase on multiple lactosamine re-
peats (29). The peak eluted at the size of tetrasaccharides was
identified as Galb134[Fuca133]GlcNAcb133Gal, because it
is converted to a monosaccharide only by the sequential action
of almond meal a-fucosidase, D. pneumoniae b-galactosidase,
and D. pneumoniae b-N-acetylglucosaminidase. The larger
peaks (fractions 51–55 and 46–50 in Fig. 4, upper panel) con-
tain one and two other major oligosaccharides, respectively.
They were identified by sequential exoglycosidase digestions
and Bio-Gel P-4 filtration as the pentasaccharide, hexasaccha-
ride, and heptasaccharide already reported (26). Such oligosac-
charides contain double lactosamine repeats fucosylated on the
inner GlcNAc, a substitution that makes the Galb134GlcNAc
linkage resistant to endo-b-galactosidase under usual reaction
conditions (30). These results strongly suggest that the
(6NeuAca233)Galb133[Fuca134]GlcNAcb133Gal oligosac-
charide synthesized in CHO-FT-T5 replaces the poly-N-
acetyllactosamine chains and sLex structure present in CHO-
FT-T1 as well as in CHO cells expressing Fuc-TIII only. To
assess the presence of type 1 chain carbohydrates in endo-b-
galactosidase-resistant N-glycans, we have determined the
amount of radioactive Gal released by X. manihotis b-galacto-
sidase. As shown in Table III, X. manihotis b-galactosidase is
active only on the glycans derived from CHO-FT-T5, but not on
those from CHO-FT-T1. The amount of Gal released by the
enzyme is strongly dependent on the concurrent action of siali-
dase, but not on that of a-fucosidase, and is much lower than
that released by D. pneumoniae b-galactosidase under the
same reaction conditions. These results indicate that type 1
chains synthesized on endo-b-galactosidase-resistant N-gly-
cans by b3Gal-T5 are present in limited amount and are not
significantly substituted by fucose residues.
In Vitro Properties of b3Gal-T5—Using a cell homogenate
prepared from COS cells transiently transfected with b3Gal-T5
cDNA as the enzyme source, we determined the optimal reac-
tion conditions using GlcNAc as acceptor and found that the
activity requires Mn21, is maximal at neutral pH, is saturated
by donor UDP-Gal concentrations above 0.5 mM, and is not
affected by a-lactalbumin. Under the same reaction conditions,
various oligosaccharides are also used. The obtained reaction
products are over 95% affected by X. manihotis b-galactosidase
and almost unaffected by D. pneumoniae b-galactosidase. In
the presence of the proper detergent concentration, the same
homogenate very efficiently transfers Gal to the glycolipid
lactotriosylceramide, and the reaction product was identified
as lactotetraosylceramide (Galb133GlcNAcb133Galb134
Glcb1319Cer) by HPTLC mobility and differential sensitivity
to b-galactosidases. The calculated Km and Vmax values (Table
IV) indicate that the enzyme prefers the GlcNAcb133Gal end
but also distinguish among the different carrier molecules,
TABLE IV
Kinetic properties of b3Gal-T5




GlcNAc 161 853 5.3
GlcNAcb133Galb13O-methyl 0.45 788 1751
GlcNAcb133Galb134Glc 1.91 755 395
GlcNAcb132Man 20.9 825 39.5
GlcNAcb136Mana13O-methyl 34.7 1034 29.8
Lactotriosylceramide 0.34 1347 3961
TABLE III
[3H]Gal released by D. pneumoniae or X. manihotis b-galactosidase treatment of endo-b-galactosidase resistant N-glycans
prepared from CHO clones
The whole reaction mixtures (about 5000 cpm) were applied to Bio-Gel P-2 column, and radioactivity in the eluted fractions was determined by
liquid scintillation counting. Results are the means for two independent experiments and are presented as percentage of recovered radioactivity
in the galactose peak.
Condition
CHO-FT-T5 CHO-FT-T1
D. pneumoniae X. manihotis D. pneumoniae X. manihotis
%
Alone ,5 ,5 7.4 ,5
Plus sialidase 50.5 17.4 45.3 ,5
Plus fucosidase ,5 ,5 6.8 ,5
Plus sialidase and fucosidase 48.2 14.3 47.2 ,5
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with a preference for the glycolipid acceptor. GlcNAc linked to
a-Man through b1,2- or b1,6-linkages is also a suitable accep-
tor, but with much lower affinity. These in vitro results are in
good agreement with those obtained by the structural analysis
of CHO-FT-T5 clone, where we found that endo-b-galactosid-
ase-sensitive saccharides, having the GlcNAcb133Gal accep-
tor sequence, are preferentially operated upon by b3Gal-T5,
whereas endo-b-galactosidase-resistant N-glycans, mostly hav-
ing GlcNAcb132/6Man as acceptor sequences, are poorly
utilized.
Expression of b3Gal-T5 Transcript in Normal Colon Mu-
cosa and in Adenocarcinomas—To evaluate whether the
b3Gal-T5 transcript is differentially expressed during carci-
nogenesis, we analyzed its amount by competitive RT-PCR
performed on total RNA extracted from human colon speci-
mens collected at surgery, representing both adenocarcino-
mas and surrounding normal mucosa. Clinical features and
tumor staging are outlined in Table V. The b3Gal-T5 tran-
script is detected in all normal mucosa samples, although it is
faintly detectable or undetectable in adenocarcinomas whose
cDNA is well amplified using control primers such as those
for b-actin or other glycosyltransferases (Fig. 5). In quanti-
tative terms (Fig. 6), the b3Gal-T5 transcript is on the aver-
age 30-fold less expressed in adenocarcinomas than in
normal mucosa. In individual cases, the levels in adenocar-
cinomas range from 4-fold to over 100-fold less than in nor-
mal mucosa. For comparison we looked at the expression
levels of the other b3Gal-T transcripts, as well as of Fuc-TIII
and FUT2, two fucosyltransferases involved in type 1 chain
fucosylation. b3Gal-T4 transcript is expressed at high and
heterogeneous levels in normal mucosa and remains detect-
able in all adenocarcinomas. b3Gal-T1 transcript is detecta-
ble in eight normal mucosa and four adenocarcinoma cases,
whereas b3Gal-T2 transcript is detectable in four normal
mucosa and seven adenocarcinoma cases. b3Gal-T3, Fuc-
TIII, and FUT2 transcripts are heterogeneously expressed in
both normal mucosa and adenocarcinomas. Altogether, these
data suggest that the b3Gal-T5 transcript, almost undetect-
able in colon adenocarcinomas, is strongly down-regulated
during carcinogenesis.
Characterization of CEA Purified from a CHO Clone Express-
ing b3Gal-T5—To study the ability of b3Gal-T5 to act on CEA,
a CHO clone permanently expressing this antigen, as well as
b3Gal-T5 and Fuc-TIII, was obtained by transfecting CHO-
FT-T5 cells with CEA (CHO-FT-T5-CEA). As assessed by flow
cytometry, the expression levels of sLea and Lea antigens in
this clone are identical to those of the starting one, whereas
those of CEA were comparable to that of human cancer cell
lines. In particular, we measured a mean fluorescence intensity
lower than in MKN-45 cells, but higher than in COLO-205 cells
(not shown). The tritiated material purified from clone CHO-
FT-T5-CEA metabolically radiolabeled with [3H]Gal runs on
SDS-PAGE as a single radioactive band of an apparent molec-
ular mass of 200 kDa (Fig. 7). Immunoblot analysis shows that
this band strongly reacts with anti-CEA antibody. Sequential
stripping and reprobing of the filter with anti-Lewis antigen
antibodies reveals that the purified CEA reacts with anti-sLea
but not with anti-sLex antibodies, indicating that type 1 chains
are specifically present on CEA expressed in the clone. To
directly assess the presence of type 1 chain carbohydrates on
CEA and to determine whether they are preferentially bound to
GlcNAcb133Galb134GlcNAcb13R outer sequences, the pu-
rified [3H]CEA, once de-fucosylated and de-sialylated, was
treated with different b-galactosidases before and after endo-
b-galactosidase treatment. To this end, the endo-b-galactosid-
ase reaction mixture was submitted to Bio-Gel P-2 filtration
and the endo-b-galactosidase-resistant and -sensitive radioac-
tivity was recovered with the exclusion volume and at the size
TABLE V
Major clinical features of the patients with colon adenocarcinoma whose biopsy were analyzed by competitive RT-PCR
Case Age Sexa Localization Gradeb Stage (Dukes’) CEAc CA19.9d
ng/ml units/ml
1 61 F Splenic flexure G2 C2 5.3 72.9
2 75 M Hepatic flexure G2 C2 53.2 84.6
3 69 M Rectum G2 B2 NAe NA
4 76 F Cecum G3 C2 60.5 19.2
5 64 F Ascending colon G2 B2 4.7 115
6 78 M Ampulla recti G2 B2 NA NA
7 77 M Cecum G2 D NA NA
8 77 F Ascending colon G2 B2 NA NA
9 66 F Sigmoid colon G2 B2 NA NA
10 65 F Rectum G3 C1 NA NA
a M, male; F, female.
b G2, moderately differentiated; G3, poorly differentiated.
c Normal range ,5.0 ng/ml.
d Normal range ,37 units/ml.
e NA, not available.
FIG. 5. Competitive RT-PCR analysis of b3Gal-T5 transcript in
normal mucosa and in adenocarcinomas. RNA extracted from
adenocarcinomas and surrounding normal mucosa, collected at surgery,
was reverse-transcribed, and the obtained first strand cDNA was mixed
with competitor (truncated) cDNAs (5 pg and 20 fg for b-actin and
glycosyltransferases, respectively), and subjected to PCR (25 and 35
cycles for b-actin and glycosyltransferases, respectively). Primers and
PCR product length are indicated in Table I. One-fifth aliquot of each
amplification reaction was electrophoresed in 1% agarose gel and visu-
alized by staining with ethidium bromide. N, normal mucosa; A, ade-
nocarcinoma. Numbers denote patients according to Table V. Samples
1–6 and 7–10 were run on different gels.
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of trisaccharides, respectively (Fig. 8, upper panel). A small but
detectable amount of Gal was removed by X. manihotis b-ga-
lactosidase from total de-sialylated and de-fucosylated CEA,
and the amount released from the endo-b-galactosidase-resist-
ant material (fractions 18–22 in Fig. 8) was minimal, whereas
that released by D. pneumoniae b-galactosidase was more con-
sistent in both cases. Conversely, almost 40% of the radioac-
tivity from the endo-b-galactosidase-sensitive trisaccharide
(fractions 32–39 in Fig. 8) was released by X. manihotis b-ga-
lactosidase, but poorly affected by the diplococcal enzyme (Fig.
8, lower panel). These data indicate that b3Gal-T5 preferen-
tially acts on the GlcNAcb133Galb134GlcNAcb13R side
chains present in CEA.
DISCUSSION
This report shows that b3Gal-T5, in transfected CHO cells,
directs synthesis of type 1 chain oligosaccharides on CEA and
other N-glycans having the GlcNAcb133Galb13
4GlcNAcb13R outer sequence, prevents poly-N-acetyllac-
tosamine and sLex synthesis on N-glycans, and is down-
regulated in colon adenocarcinomas.
We have found that b3Gal-T5 synthesizes sLea and Lea an-
tigens very efficiently in CHO cells, much more than b3Gal-T1,
which is still more efficient than b3Gal-T2, whereas b3Gal-T3
and -T4 are unable to synthesize these antigens at all. In the
stable clone CHO-FT-T5, sLea expression is selectively affected
by swainsonine, an inhibitor of complex type N-glycan process-
ing (31), but not by benzyl-a-GalNAc, an inhibitor of O-glycan
biosynthesis (32), although the opposite occurs in clone CHO-
FT-T1. These data support the hypothesis that b3Gal-T5 acts
on complex type N-glycans in CHO cells and suggest that
b3Gal-T1 presumably affects unknown O-glycans available in
these cells in a low amount. In this regard, it is interesting that
sLea expression in CHO-FT-T1 is strongly stimulated by so-
dium butyrate, a commonly used activator reported to enhance
core 2 GnT activity in CHO cells (33). However, results ob-
tained with CHO-FT-T2 suggest that b3Gal-T2 requires dedi-
cated substrates not available in these cells. Moreover, CHO-
FT-T1 cells, as well as CHO-FT-T2, were found to express a
large amount of sLex that is undetectable in CHO-FT-T5. We
found that the oligosaccharides released from N-glycans by
endo-b-galactosidase are completely different in the clones. In
fact, (6NeuAca233)Galb133[Fuca134]GlcNacb133Gal is
the only oligosaccharide identified in CHO-FT-T5, whereas in
clone CHO-FT-T1 several oligosaccharides are released, which
correspond to those reported in CHO expressing Fuc-TIII only
(26). They include the sLex tetrasaccharide as well as poly-N-
acetyllactosamine side chains, but not type 1 chain oligosac-
charides. Among endo-b-galactosidase-resistant N-glycans,
type 1 chain oligosaccharides are present in small amounts and
not fucosylated in clone CHO-FT-T5 but not detectable in CHO-
FT-T1 cells. On this basis we conclude that the expression of
FIG. 6. Competitive RT-PCR quantification of glycosyltrans-
ferase transcripts expressed in normal colon mucosa and in
adenocarcinomas. Quantification was performed by densitometric
scanning of the negative films of gels in Fig. 5. The amounts of amplified
target cDNAs were calculated from their respective standard curves
and normalized by those for b-actin. Numbers denote patients according
to Table V. Note the different scales used.
FIG. 7. SDS-PAGE of CEA purified from clone CHO-FT-T5-
CEA. CHO-FT-T5 cells were transfected with human CEA cDNA and a
clone expressing CEA, named CHO-FT-T5-CEA, was isolated and met-
abolically radiolabeled with [3H]Gal. Radioactive material recovered
upon phosphatidylinositol-specific phospholipase C extraction, perchlo-
ric acid precipitation, and Sepharose CL6B chromatography was de-
salted on a Bio-Gel P-2 column, and 10,000-cpm aliquots were loaded on
two lanes of a 6% SDS-PAGE. After the run, one lane was processed for
fluorography using liquid En3Hance (PerkinElmer Life Sciences) (10-
day exposure). The other one was blotted onto a nitrocellulose filter that
was probed with monoclonal anti-CEA antibody using peroxidase-con-
jugated goat anti-mouse Ig as secondary antibody, and visualized by
ECL. The same filter was stripped and reprobed sequentially with
monoclonal anti-sLea and anti-sLex antibodies.
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b3Gal-T5 in CHO cells inhibits the synthesis of poly-N-
acetyllactosamines and sLex in N-glycans, replacing them with
a short type 1 chain, whereas that of b3Gal-T1 does not affect
N-glycans. Expression of N-linked poly-N-acetyllactosamines,
which are often modified to express functional oligosaccharides
such as sLex, is considered to be associated with tumor pro-
gression and malignancy (34). Recent work on poly-N-acetyllac-
tosamine extension in N-glycans (35) demonstrated that it is
achieved mainly by b4Gal-T1 and b1,3-N-acetylglucosaminyl-
transferase iGnT (36) and is favored by b1,6GlcNAc branching,
because the branched structure serves as a much better accep-
tor for such enzymes (37). Expression of GlcNAc-TV, responsi-
ble for branching, also correlates with metastatic potential of
cell lines (38) as well as with metastasis and poor prognosis in
colon cancer (39). Because b3Gal-T5 has a very high affinity for
acceptors having the GlcNAcb133Gal outer sequence, but
much lower for those with the GlcNAcb132Man or
GlcNAcb136Man sequence, the following scenario can be en-
visaged in CHO cells. In the presence of b3Gal-T5, b4Gal-T1
still acts on GlcNAc linked to Man, and complex type N-glycans
are elongated by a single lactosamine unit. This is acted upon
by iGnT, presumably on a b1,6-branched chain, which forms
the GlcNAcb133Galb134GlcNAcb13R outer group. At this
stage, b3Gal-T5 competes with b4Gal-T1 adding a b1,3-galac-
tosyl residue that prevents further chain elongation by iGnT.
Consequently, poly-N-acetyllactosamine chains could not be
efficiently extended nor sLex synthesized.
It is worth noting that the Km values of b3Gal-T5 for
GlcNAcb133Galb134Glc and GlcNAcb132Man are virtually
identical to those reported for a b1,3Gal-T expressed in normal
colon mucosa whose activity was found low in adenocarcinomas
(5). These data prompted us to evaluate the expression level of
b3Gal-T5 transcript in normal mucosa versus colon adenocar-
cinomas. Competitive RT-PCR analysis performed on 10 colon
adenocarcinoma cases indicate that b3Gal-T5 transcript is con-
stantly down-regulated in cancer, confirming that it is the
enzyme previously detected by Seko et al. (5) and corroborating
the hypothesis that in vivo it would prevent the expression of
poly-N-acetyllactosamines and sLex on N-glycans. This behav-
ior is unique among b3Gal-T and other glycosyltransferase
transcripts studied to date (40–43).
Because CEA synthesized in normal mucosa is reported to
express N-glycans having type 1 chains as Galb133GlcNAcb13
3Galb134GlcNAcb13R outer sequences (3, 4), whereas CEA
produced by colon adenocarcinomas lacks type 1 chains but
have poly-N-acetyllactosamine and b1,6 branched type 2
chains on N-glycans (2, 44), our results suggest that b3Gal-T5
may act on CEA in vivo. To assess this hypothesis, we perma-
nently expressed CEA in clone CHO-FT-T5 (CHO-FT-T5-CEA).
We found that CEA purified from the clone reacts with anti-
sLea antibody by Western blot. Moreover, the type 1 chain
carbohydrates present in the molecule are more abundant in
endo-b-galactosidase-sensitive oligosaccharides than in those
resistant. These results confirm that b3Gal-T5 acts on CEA
and suggest that it is responsible for the differential glycosy-
lation pattern of this protein in colon cancer.
The kinetic data calculated in this paper for lactotriosylcer-
amide, as well as those reported (20) for GlcNAcb133GalNAc
as acceptors, suggest that b3Gal-T5 is able to act on glycolipids
as well as on core 3 O-linked glycoproteins. The possibility of a
broad range of specificity of the enzyme is confirmed by the
recent report that it also acts on the GalNAc end of globote-
traosylceramide (45). On this basis, the down-regulation of
b3Gal-T5 in cancer is expected to affect other glycoconjugates
synthesized by the enzyme in normal mucosa. However, b3Gal-
T5 expression is maintained in some colon adenocarcinoma cell
lines (16), and we suggest that the results obtained with these
cells must be cautiously interpreted, or reinterpreted (12, 19).
In particular, further experimental data are needed to estab-
lish whether or not the CA19.9 antigen present in patient
serum is synthesized by b3Gal-T5 and secreted from the tumor
mass.
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